New data from phase 3 trials of monoclonal antibodies for patients with recent COVID-19 diagnoses, or at high risk for SARS-CoV-2 infection, could move the needle on clinician acceptance of the treatments, experts say. Two monoclonal antibody formulations, Eli Lilly's bamlanivimab and Regeneron's cocktail of two antibodies, casirivimab and imdevimab, received emergency use authorizations from the US Food and Drug Administration in November to treat mild to moderate COVID-19 in outpatients. But current recommendations from the Infectious Diseases Society of America's COVID-19 treatment and guideline panel, based on data from a phase 2 trial of bamlanivimab, suggest against the routine...